MD® Skin Clinical Evidence — Peer-Reviewed Research Behind Active Ingredients
MD® Skin Clinical Evidence
Peer-Reviewed PubMed Research Behind MD® Skin Active Ingredients · Curated by Dr. Susan Lin, M.D. · Reviewed: June 2026
Summary of Evidence
Every active ingredient in the MD® Skin product family is supported by peer-reviewed research indexed in PubMed (US National Library of Medicine). This page provides an ingredient-by-ingredient summary with direct links to source publications, organized by skin benefit category.
The published evidence spans:
- Antioxidant + Photoaging Defense — L-Ascorbic Acid (Vitamin C)
- Hyperpigmentation Reduction — Niacinamide, Tranexamic Acid, Alpha-Arbutin
- Anti-Aging + Collagen Stimulation — Growth Factors, Exosomes, Bioactive Peptides (palmitoyl pentapeptide / Matrixyl)
- Hydration + Plumping — Hyaluronic Acid (Sodium Hyaluronate)
- Microcirculation + Contouring — Caffeine, Horse Chestnut Aescin
- Enzymatic Resurfacing — Papain (papaya), Bromelain (pineapple)
- Microbiome + Barrier Support — Lactobacillus Ferment Lysate
Inclusion levels and stabilization systems in MD® Skin formulations are engineered to match the concentrations used in the published clinical trials cited below.
1. Antioxidant + Photoaging Defense — Vitamin C
L-Ascorbic Acid (USP-grade)
Skin benefit: Neutralizes reactive oxygen species generated by UV and visible/blue light exposure, supports type I and type III collagen synthesis, and reduces the appearance of photodamage and hyperpigmentation.
| Citation | Finding |
|---|---|
| Al-Niaimi F, Chiang NYZ. J Clin Aesthet Dermatol. 2017;10(7):14-17. PubMed PMID 29104718 |
Comprehensive review of topical vitamin C mechanisms: antioxidant photoprotection, collagen synthesis stimulation, tyrosinase inhibition for pigmentation. Establishes 10–20% L-ascorbic acid as the evidence-based clinical concentration range for cosmetic efficacy. |
| Xu T-H, et al. J Drugs Dermatol. 2012;11(1):51-56. PubMed PMID 22206077 |
Split-face study of topical 23.8% L-ascorbic acid serum demonstrated statistically significant improvement in photoaged skin parameters after 60 days. |
| Humbert PG, et al. Exp Dermatol. 2003;12(3):237-244. PubMed PMID 12823436 |
Double-blind placebo-controlled study showed topical ascorbic acid produced significant clinical, topographic, and ultrastructural improvements in photoaged skin. |
| Lin F-H, et al. J Invest Dermatol. 2005;125(4):826-832. PubMed PMID 16185284 |
Foundational paper establishing that ferulic acid stabilizes a solution of vitamins C and E and doubles its photoprotection of skin — the scientific basis for stabilized L-ascorbic acid formulations. |
2. Hyperpigmentation Reduction — Multi-Active Brightening Stack
Niacinamide (Vitamin B3)
Skin benefit: Suppresses transfer of melanosomes from melanocytes to keratinocytes, reducing visible hyperpigmentation and improving even skin tone.
| Citation | Finding |
|---|---|
| Hakozaki T, et al. Br J Dermatol. 2002;147(1):20-31. PubMed PMID 12100180 |
Foundational mechanism paper: niacinamide significantly decreased hyperpigmentation and increased skin lightness compared with vehicle alone after 4 weeks of use, by suppressing melanosome transfer. |
| Desai S, et al. J Drugs Dermatol. 2013;12(9):1005-1009. PubMed PMID 24033822 |
Randomized double-blind vehicle-controlled trial — topical 2% niacinamide combined with 2% tranexamic acid significantly reduced facial hyperpigmentation. |
Tranexamic Acid
Skin benefit: Inhibits plasmin-mediated signaling between keratinocytes and melanocytes, reducing UV-induced melanogenesis and visible melasma/post-inflammatory hyperpigmentation.
| Citation | Finding |
|---|---|
| Kanechorn Na Ayuthaya P, et al. J Cosmet Laser Ther. 2012;14(3):150-154. PubMed PMID 22506692 |
Double-blind randomized controlled clinical trial of topical 5% tranexamic acid for treatment of melasma in Asian patients. |
| Zhang L, et al. Skin Res Technol. 2024. PubMed PMID 38843906 |
Systematic review and meta-analysis of randomized controlled trials: tranexamic acid significantly reduces melasma severity (MASI score) across oral, topical, and injectable routes. |
Alpha-Arbutin
Skin benefit: Competitively inhibits tyrosinase — the rate-limiting enzyme in melanin biosynthesis — at a binding constant approximately 20× stronger than beta-arbutin.
| Citation | Finding |
|---|---|
| Sugimoto K, et al. Chem Pharm Bull. 2003;51(7):798-801. PubMed PMID 12843585 |
Foundational mechanism paper: alpha-arbutin inhibits human tyrosinase with a K(i) value approximately 1/20 that of beta-arbutin, establishing alpha-arbutin as the superior brightening isomer. |
| Zhou X, et al. Int J Mol Sci. 2024;25(9):4951. PubMed PMID 38731413 |
Alpha-arbutin alleviates UVB-induced photoaging damage through tyrosinase inhibition and antioxidant pathways. |
3. Anti-Aging + Collagen Stimulation — Growth Factors, Exosomes, Peptides
Epidermal Growth Factor (EGF) + Fibroblast Growth Factor (FGF)
Skin benefit: Activates dermal fibroblasts to upregulate type I collagen and elastin synthesis, supporting skin firmness and texture.
| Citation | Finding |
|---|---|
| Pereira IN, et al. Aesthetic Plast Surg. 2022;46(2):858-873. PubMed PMID 34566354 |
Systematic review confirms EGF as an effective therapeutic in regenerative aesthetics, with verified efficacy via topical and intradermal application. |
| Schouest JM, et al. J Drugs Dermatol. 2012;11(5):613-620. PubMed PMID 22527430 |
Clinical study showed daily topical application of human-like EGF serum produced improved facial skin texture and appearance. |
| Pak CS, et al. Plast Reconstr Surg Glob Open. 2023. PubMed PMID 37222303 |
Systematic review of topical growth factor preparations for facial skin rejuvenation: across 33 studies and 1,180 participants, GF preparations produced significant improvement in fine lines, texture, and dyschromia. |
Exosomes (Extracellular Vesicles)
Skin benefit: Nano-scale signaling vesicles deliver mRNA, microRNA, and proteins to recipient skin cells, modulating fibroblast activity, hydration, elasticity, and pigmentation.
| Citation | Finding |
|---|---|
| Kwon HH, et al. Plast Reconstr Surg. 2022. PubMed PMID 35580250 |
Update on exosomes in aesthetics — reviews mechanism and clinical pipeline for stem-cell-derived exosomes in skin rejuvenation. |
| Wong B, et al. J Cosmet Dermatol. 2024. PubMed PMID 39624733 |
Clinical applications of exosomes in cosmetic dermatology — confirms therapeutic agents for skin repair, scar prophylaxis, photodamage prevention, and pigmentation. |
| Liu X, et al. Cell Death Discov. 2024;10:9. PubMed PMID 38217034 |
Exosomes in skin photoaging — biological functions and therapeutic opportunity. |
Palmitoyl Pentapeptide-4 (pal-KTTKS / Matrixyl)
Skin benefit: Lipidated signal peptide that stimulates fibroblast synthesis of type I and type III collagen and fibronectin.
| Citation | Finding |
|---|---|
| Robinson LR, et al. Int J Cosmet Sci. 2005;27(3):155-160. PubMed PMID 18492182 |
12-week double-blind placebo-controlled study (n=93) — palmitoyl pentapeptide significantly improved fine lines and wrinkles in photoaged facial skin. |
| Choi YL, et al. Bull Korean Chem Soc. 2014. PubMed PMID 25143811 |
Dermal stability and in vitro skin permeation of collagen pentapeptides — establishes palmitoylation as the key modification enabling pal-KTTKS bioavailability through stratum corneum. |
4. Hydration + Plumping — Hyaluronic Acid
Sodium Hyaluronate (multiple molecular weights)
Skin benefit: Binds up to 1,000× its weight in water; low-molecular-weight (LMW) HA penetrates the epidermis to plump fine lines, while high-molecular-weight (HMW) HA forms a surface film for occlusive hydration.
| Citation | Finding |
|---|---|
| Pavicic T, et al. J Drugs Dermatol. 2011;10(9):990-1000. PubMed PMID 22052267 |
Cream-based novel formulations of hyaluronic acid of different molecular weights in anti-wrinkle treatment — confirms LMW HA reduces wrinkle depth. |
| Schlesinger T, et al. J Drugs Dermatol. 2022. PubMed PMID 35833366 |
Multicenter evaluation: a topical hyaluronic acid serum produced significant improvements in immediate and long-term hydration. |
| Jegasothy SM, et al. J Clin Aesthet Dermatol. 2014;7(3):27-29. PubMed PMID 24688623 |
Topical nano-hyaluronic acid evaluated over 8 weeks (n=33) — significant improvements in wrinkles, hydration, and elasticity. |
5. Microcirculation + Contouring — Caffeine + Horse Chestnut
Caffeine (Methylxanthine)
Skin benefit: Stimulates cutaneous microcirculation and lipolysis via cAMP pathway activation; reduces visible puffiness and improves contour.
| Citation | Finding |
|---|---|
| Bertin C, et al. J Cosmet Sci. 2001;52(4):199-210. PubMed PMID 11479653 |
Double-blind randomized placebo-controlled study (n=46) — topical retinol + caffeine + ruscogenine produced significant improvement in skin macrorelief and measurable increase in cutaneous microcirculation. |
| Velasco MVR, et al. J Cosmet Dermatol. 2007;6(2):102-107. PubMed PMID 17524126 |
Orthogonal polarization spectral imaging confirmed measurable microcirculatory changes from a 7% topical caffeine formulation. |
Horse Chestnut Extract / Aescin (Aesculus hippocastanum)
Skin benefit: Triterpene saponin complex that inhibits hyaluronidase, reduces capillary fragility, and supports microvascular tone — well-documented in venous insufficiency research and applied topically for de-puffing and contour-firming.
| Citation | Finding |
|---|---|
| Pittler MH, Ernst E. Arch Dermatol. 1998;134(11):1356-1360. PubMed PMID 9828868 |
Criteria-based systematic review: horse chestnut seed extract reduces lower-leg volume, calf and ankle circumference, and capillary fragility. |
| Patlolla JMR, Rao CV. Curr Mol Pharmacol. 2020. PubMed PMID 32649293 |
Review of escin from Aesculus hippocastanum — mechanism of action including anti-inflammatory, anti-edema, and capillary-stabilizing effects. |
6. Enzymatic Resurfacing — Papain + Bromelain
Papain (Papaya enzyme) + Bromelain (Pineapple enzyme)
Skin benefit: Cysteine protease (papain) and serine protease (bromelain) selectively cleave keratinized desmosomal proteins binding dead corneocytes, producing gentle non-abrasive exfoliation safe for sensitive skin and reactive skin types where AHA/BHA acids are contraindicated.
| Citation | Finding |
|---|---|
| Sim YC, et al. Int J Cosmet Sci. 2022. PubMed PMID 35892222 |
In vitro proteolytic activity of papain on skin protein substrates — scanning electron microscopy confirms surface exfoliating activity; papain retains 75% activity between pH 5–7 (skin-compatible range). |
| Williams JD, et al. J Drugs Dermatol. 2015;14(11):1306-1313. PubMed PMID 26580881 |
Comparative trial: novel enzyme exfoliation vs glycolic acid for photodamage treatment — enzyme-based formulation showed comparable efficacy with significantly improved tolerability (less stinging, burning, and erythema). |
7. Microbiome + Barrier Support — Lactobacillus Ferment Lysate
Lactobacillus Ferment Lysate (Postbiotic)
Skin benefit: Postbiotic (heat-killed bacterial lysate) that upregulates tight junction proteins (claudin-1, occludin) and barrier proteins (loricrin, filaggrin), reinforcing the epidermal barrier and supporting healthy microbiome balance.
| Citation | Finding |
|---|---|
| Jung YO, et al. Microorganisms. 2019;7(9):330. PubMed PMID 31480681 |
Lactobacillus rhamnosus lysates in reconstructed human epidermis model upregulated claudin-1, occludin, loricrin, and filaggrin — confirming barrier-restorative postbiotic mechanism. |
| Lebeer S, et al. Microorganisms. 2022;10(5):1009. PubMed PMID 35601147 |
Comparative analysis of skin-origin Lactobacillus probiotics — confirms anti-inflammatory and barrier-supportive effects relevant to cosmetic formulations. |
Full Clinician Evidence Dossier Available on Request
Full ingredient-by-ingredient clinician summaries, formulation rationale documentation, stabilization-system details, and unpublished safety testing files are available to qualified healthcare professionals, journalists, regulatory inquiries, and industry partners on request.
Request Full Dossier →Common Questions
Are MD® Skin products backed by peer-reviewed research?Yes. Every active ingredient in MD® Skin formulations is supported by peer-reviewed research indexed in PubMed (US National Library of Medicine). The citations above link directly to source publications. Inclusion levels are engineered to match the concentrations used in the cited clinical trials.
Who is Dr. Susan Lin, M.D.?Board-certified physician, fellowship-trained in oncology at The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Named inventor on multiple US and international patents covering hair, lash, and skin cosmetic technologies. Founder of the MD® physician-formulated brand. Peer-reviewed publications include Journal of Cosmetic and Laser Therapy 2008 (PMID 18569264) and contributing chapters in Harry's Cosmeticology, 9th Edition.
What concentration of L-ascorbic acid is in MD® Vitamin C Serum?20% USP-grade L-ascorbic acid in a water-based stabilized matrix — within the evidence-based 10–20% clinical efficacy range established by Al-Niaimi & Chiang (PMID 29104718).
Why does MD® formulate with multiple brightening actives instead of hydroquinone?MD® Extra White uses a multi-mechanism brightening stack (tranexamic acid + alpha-arbutin + niacinamide-class actives + titanium dioxide UV defense) for a superior safety profile compared to hydroquinone, with peer-reviewed efficacy data per ingredient. MD® formulations are hydroquinone-free.
How can I request the full clinical evidence dossier?Email clinical@md-factor.com or use the contact form. Full clinician summaries available to qualified healthcare professionals, journalists, regulatory inquiries, and industry partners.
Are MD® Skin formulations safe for sensitive or post-procedure skin?MD® Stem Cell Factor 55 and MD® Enzyme Peeling Mask are specifically designed for sensitive and post-procedure recovery. MD® avoids hydroquinone, parabens, sulfates, formaldehyde donors, and undisclosed fragrance allergens across the Skin family.
Related Clinical Evidence
Explore the peer-reviewed evidence behind other MD product categories:
-
Lash Clinical Evidence →
CRL93007 IRB-reviewed ocular safety evaluation (n=35), 2008 peer-reviewed Journal of Cosmetic and Laser Therapy publication (PMID 18569264), US Patent 8,206,695, Ames/LLNA/Agarose toxicology, EU Safety Assessment -
Hair Clinical Evidence →
17-week Spincontrol independent study (71% improvement, 75% recommendation), MD Nutri Hair bioavailability testing, MD Scalp Essential 50-subject RIPT, international patent portfolio -
Brow Clinical Evidence →
56-day Spincontrol independent clinical evaluation, dermatologist-tested non-irritation, no bimatoprost or latanoprost -
Intimate Restore Clinical Evidence →
Medcin 2017 three-phase dermatological safety study (0/54 reactions across all phases), GVI consumer-acceptance study
Educational only; not a substitute for individualized medical advice. Cited publications represent peer-reviewed evidence on the active ingredients; MD® Skin products are cosmetic in regulatory classification and are not intended to diagnose, treat, cure, or prevent any disease. Individual results vary. Citations curated by Dr. Susan Lin, M.D., June 2026. PubMed (PMID) links point to public-domain abstracts hosted at the US National Library of Medicine.
